Market Segment
$2.1B to $8.7B
Growth window 2025 to 2032.
Senolytics
Core therapeutic focus on selective clearance of senescent cells with AI-supported discovery and validation.
Target Timeline
4 to 6 years
Accelerated path vs. traditional discovery.
Selectivity Goal
>95%
Prioritized senescent-cell specificity.
Scientific Rationale
Senescent cells accumulate with age and drive inflammatory signaling (SASP). This is associated with multiple age-related disorders and reduced tissue resilience.
Current Gaps We Address
- Insufficient tissue specificity of first-generation compounds.
- Off-target effects that narrow therapeutic windows.
- Low predictive power in early candidate triage.
Program Structure
- AI-based compound triage from large libraries.
- High-throughput testing across multiple senescent cell contexts.
- Progression to translational packages for partner-ready programs.